Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label surovatamig study in anti-PLA2R-positive primary membranous nephropathy
2025-524139-38-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of surovatamig in idiopathic membranous glomerulonephritis (IMG), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Change from baseline in UPCR at 6 months. Planned start Jul 2026; status: authorised.
02
Drugs
surovatamig
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2025-524139-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524139-38-00.